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Purpose: To investigate the inﬂuence of interfractional changes on the delivered dose of intensity
modulated proton (IMPT) and photon plans (IMXT).
Methods and materials: Five postoperative head and neck cancer patients, previously treated with
tomotherapy at our institute, were analyzed. The planning study is based on megavoltage (MV) control
images. For each patient one IMPT plan and one IMXT plan were generated on the ﬁrst MV-CT and
recalculated on weekly control MV-CTs in the actual treatment position. Dose criteria for evaluation were
coverage and conformity of the planning target volume (PTV), as well as mean dose to parotids and
maximum dose to spinal cord.
Results: Considerable dosimetric changes were observed for IMPT and IMXT plans. Proton plans showed
a more pronounced increase of maximum dose and decrease of minimum dose with local underdosage
occurring even in the center of the PTV (worst IMPT vs. IMXT coverage: 66.7% vs. 85.0%). The doses to
organs at risk (OARs) increased during the treatment period. However, the OAR doses of IMPT stayed
below corresponding IMXT values at any time. For both modalities treatment plans did not necessarily
worsen monotonically throughout the treatment.
Conclusions: Although absolute differences between planned and reconstructed doses were larger in
IMPT plans, doses to OARs were higher in IMXT plans. Tumor coverage was more stable in IMXT plans;
IMPT dose distributions indicated a high risk for local underdosage during the treatment course.
© 2015 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Interfractional changes of patient anatomy, due to patient
weight loss and shrinkage of the tumor and structures nearby, as
well as variations in daily set-up, are of concern in radiotherapy. In
order to retain dosimetric quality during the treatment phase,tion Oncology, Technische
maninger Straße 22, 81675
þ49 (0) 89 4140 4881.
e (B.S. Müller).
ica. Published by Elsevier Ltd. Thisimage guided radiotherapy (IGRT) and adaptive planning are a part
of clinical practice.
Head and neck patients are known to be subject to severe
anatomical changes throughout the treatment course and therefore
beneﬁt from frequent controls [1-6]. Their treatment plans are
often strongly modulated, i.e. featuring steep dose gradients within
ﬁelds which may even be more sensitive to geometrical changes
[3,5,7]. So far there is no standard solution on how often controls
have to be performed, when to adapt a plan and which patients
beneﬁt from plan adaptions.
Depending on the applied irradiation technique anatomical
changes may have different degrees of impact. Dose distributions in
intensity modulated proton therapy (IMPT) are often superioris an open access article under the CC BY-NC-ND license (http://creativecommons.
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The Bragg peak and the well-deﬁned range of the protons allow
better sparing of healthy tissue and higher conformity of the target
volume. Nevertheless these advantageous physical properties of
protons can also be a risk in clinical practice [14e20].
Due to the different physical characteristics of photons and
protons, e.g. the sensitivity of depth dose curves to density changes
of traversed matter, it is of interest how sensitive IMPT and IMXT
plan qualities are to interfractional anatomical changes of patients
and how relevant IGRT is for both techniques.
This study focuses on IMPT and IMXT treatment plans of head
and neck cancer patients that were not adapted “in time”. We
present an analysis of dosimetric alterations due to interfractional
changes by recalculating the initial plans on control images at
different times during the treatment period.
Material and methods
Patient characteristics
This retrospective planning study was performed on data of ﬁve
postoperative head and neck cancer patients (1 hypopharynx,
2 tonsil, 1 oral cavity, 1 larynx) treated by tomotherapy (Accuray
Inc., Madison, WI) at our institute. Four of them underwent
radiochemotherapy. The clinical target volume (CTV) was deﬁned
as the GTV (gross tumor volume) on the preoperative imaging,
including the postoperative region, plus a margin of 10 mm. The
elective nodal-CTV was deﬁned according to Gregoire et al. and
Chao et al. [21,22]. The initial planning target volumes
(PTV¼CTVþ5 mm safety margin) ranged from 721.7 cm3 to
1296.7 cm3.
Patients were immobilized with a head and shoulder mask.
Daily control megavoltage (MV) CTs were acquired and merged
with the planning kilovoltage CT scan (kV-CT) before treatment.
After registration by the bone and tissue registration algorithm
provided by the tomotherapy unit, the automatic registration was
manually corrected by staff members with regard to tumor
coverage and spinal cord sparing. These images representing the
actual treatment position served as basis for our planning study
(Fig. 1).
For the contouring process on the MV-CTs the images were
imported into the Eclipse planning system (VarianMedical Systems
Inc., Palo Alto, CA). In order to minimize bias, the contouring pro-
cess on the MV-CTs was done by the same physician for all CTs. The
structures of the original PTV and organs at risk (OARs) of the kV-CT
were copied to the merged images and manually adapted to the
new anatomy.
During the treatment period (approx. 6 weeks) all patients lost
weight. The absolute amount varied during the treatment (e.g. by
saline volume expansion during chemotherapy administration),
and between patients from 2.0 kg to 12.8 kg. Similar ﬂuctuationsFigure 1. One slice of a merged CT consisting of a MV-image in the center and of small
initial kV-CT parts to ﬁll up the area outside of the (smaller) ﬁeld of view of the MV-CT.were observed for losses of PTV volumes. The mean PTV loss was
76.2 ± 50.3 cm3 (corresponding to 7.0 ± 4.6% of the initial volume)
and the greatest loss 143.1 cm3 (12.9%).Retrospective planning
Two plans were calculated for each patient, one IMPT and one
IMXT plan. The retrospective planning for both modalities was
carried out in a research version of the KonRad planning system,
developed at German Cancer Research Center in Heidelberg [23].
Planning on MV-CTs required the adaption of look-up tables
(LUT) to convert Hounsﬁeld units into water equivalent depth/
relative stopping power. The LUT data published by Newhauser [24]
served as basis for proton planning, for photon planning the clini-
cally used tomotherapy data was implemented. To avoid any
Hounsﬁeld unit calibration issues due to kV- and MV-planning and
associated LUTs all dose calculations were performed on MV-CTs,
i.e. the ﬁrst MV-CT was used as planning CT.
Proton plans were calculated using data of a virtual scanning
machine with a constant lateral beam width of 2.5 mm standard
deviation (Gaussian beam proﬁle) at the patient surface. We
selected three ﬁelds such that no proton beam traversed any parts
of the kV-CT: one posterior (180) and two lateral oblique ﬁelds
(45, 315), with spot spacing of Dx ¼ Dy ¼ Dz ¼ 0.3 cmwithin the
PTV (3D spot scanning technique [25]). The ﬁelds were optimized
simultaneously assigning the spot weights such that the combined
dose distribution fulﬁlled the deﬁned objectives as best as possible.
The IMXT plans (seven equidistant ﬁelds, 6 MV) were generated
by simultaneous ﬂuence optimization and direct translation into
multileaf collimator (MLC) segments in step and shoot mode (leaf
size: 0.5 mm). Complete blocking of kV-parts of the image was not
possible. Since the geometry of the kV image was identical for each
merged image and the inﬂuence of different LUTs for kV andMV on
the photon dose is comparatively small, the relative error between
CTs caused for IMXT planning can be neglected.
The planning and evaluation process were done on identical
target structures for IMPT and IMXT. Typically, range uncertainties
speciﬁc of IMPT can be addressed during the planning process by
additional PTV margins adjusted to beam directions. It is therefore
difﬁcult to deﬁne appropriate target structures to compare IMPT
and IMXT, as this depends on the individual study intent. Since our
goal was to study the differences in dosimetric changes over the
course of a treatment for each technique in any comparable target
structure, the photon PTV (as clinically used in our department)
served as the target volume here. The PTV accounts for setup errors,
which e even with image guidance - can never be eliminated
completely, and for internal organ motion which motivated us to
evaluate the dose delivered to this volume (rather than e.g. to the
CTV).
The initial plans were optimized by the same constraints (with
individually adjusted penalty factors): ﬁrst priority was given to
PTV coverage, (prescribed dose: 50 Gy for photons, 50 Gy(RBE) for
protons in 25 fractions). In the following all dose values are given in
Gy referring to absolute absorbed dose in case of photons and
relative biological effect (RBE ¼ 1.1) weighted dose in case of
protons. Second priority was given to the OARs, with the focus on
the spinal cord (maximum dose Dmax < 45 Gy) and parotid glands
(mean dose Dmean < 26 Gy). Sometimes objectives were not
achieved and approached at the cost of the PTV. The obtained plans,
one IMPT and one IMXT plan for each patient, were recalculated on
ﬁve MV-CTs (5th, 10th, 15th, 20th, 25th fraction) that were regis-
tered to the actual treatment position as described above.
The resulting dose distributions were analyzed in terms of dose
volume histograms (DVHs) and various indicators for the PTV and
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following indices [26]:
Coverage Index : CovI ¼ V95ðPTVÞ=VðPTVÞ
Conformity index : ConI ¼ 1þ V95ðNormal TissueÞ=V95ðPTVÞ
(V95: absolute volume in cm3 receiving 95% of the prescribed dose;
normal tissue: patient contour excluding PTV)
As to the OARs, within this paper we will focus on the spinal
cord and parotid glands. Further organs were considered, not
obtaining further conclusions though. For the spinal cord we
assessed the maximum, for the latter the mean dose. Maximum
and minimum doses were evaluated as the maximum and mini-
mum received by at least 1 cm3 of the structure.Results
Example patient
While the PTV coverage was comparably satisfying, the dose
distributions and DVHs indicated better target conformity and
preservation of OARs in the initial IMPT plan as compared to the
initial IMXT plan (Fig. 2, ﬁrst subplots of Figs. 3e6).
Throughout the treatment the homogeneity and coverage of the
PTV decreased and the areas of under- and overdosage increased
for both plans. The resulted heterogeneity was far greater for pro-
ton than for photon plans (Figs. 2 and 7). While IMPT plans revealed
underdosed spots also in the central PTV (e.g. compare recalcula-
tions on 25th CT, Fig. 2), cold spots in IMXT plans were located at
the outer PTV regions.
For both techniques the location of hot spots was not necessarily
restricted to the PTV but were also found outside - e.g. within the
parotid gland. The steepness of the DVH of the PTV degraded for
both plan types. Compared to the IMPT plans, the IMXT plansFigure 2. Dose distributions for IMPT (top row) and IMXT plans (second row) and correspon
(CT1, left) to recalculations of the last fraction (right). (Normalization: 100% ¼ 2 Gy; PTV: pchanged moderately. The quality of the DVHs did not worsen
monotonically but the plots of the 15th CT, were superior to the
10th fraction for both types of plans.PTV of all patients
The initial Dmax(1 cm3), Dmin(1 cm3) and Dmean of the PTV were
similar for the ﬁve patients for IMPT and IMXT, except for
Dmin(1 cm3) being slightly lower for photons (Fig. 3). The changes of
doses during treatment were different though. The Dmean was
almost constant at 2 Gy for both plans. The Dmax(1 cm3) increased
and Dmin(1 cm3) decreased considerably for the IMPT plans,
whereas this divergence was moderate for IMXT. Generally recal-
culated IMPT dose distributions showed extremer inhomogeneties
(Figs. 2 and 7). In the IMPT plans spots of underdosagewere located
also in the center of the PTV while in IMXT they restrained to the
boundary area. The suggested decline in homogeneity and coverage
was further supported by the increasing trend of ConI and
decreasing trend of CovI (Fig. 4). An exception were the results of
patient 5 in fraction 15: the Dmin(1 cm3) was smaller in the photon
than in the proton plan. Regarding the corresponding CovIs none-
theless this was superior to the IMPT plan.
Especially the assessed quantities of IMPT plans showed large
standard deviations, i.e. great variations between patients (Figs. 3,
4). The general trends (e.g. decreasing coverage) were still seen in
the individual patient graphs.Organs at risk of all patients
For both modalities an increasing trend of Dmax(1 cm3) to the
spinal cord was observed, the absolute changes being greater for
protons (Fig. 5). With Dmax(1 cm3) of the IMXT plans initiating at far
higher values, no proton plan reached maxima in the range of the
IMXT plans over the whole course.ding DVHs (IMPT: dashed line, IMXT: solid line) of patient no. 1: Trends from initial plan
lanning target volume).
Figure 3. Dosimetric alterations within the PTV: Dmax(1 cm3), Dmin(1 cm3) and Dmean of ﬁve patients, corresponding mean values and standard deviation over all patients (right).
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IMXT less parotid tissue was spared (Fig. 6). Since the PTV was
almost symmetrical there was no distinction between the ipsi- and
contralateral parotid gland. Overall, both modalities had an in-
crease in dose during treatment course, with smaller differences
between the planned and recalculated doses for IMXT as compared
to IMPT.
Some cases showed a decreasing Dmean (e.g. left parotid of 3rd
patient) for IMPT and IMXT, likely due to different positioning.
These ﬁndings suggest that optimizing parotid doses as low as
possible is reasonable: even if deﬁned dose limits cannot be ob-
tained, the sum of actual delivered doses might be below the ﬁrst
calculated doses.
Discussion
Recently a related study was published by Kraan et al. [15]
analyzing the impact of clinical uncertainties to IMPT plans of
oropharynx patients. A variety of scenarios of potential errors onFigure 4. Trends of coverage (CovI) and conformity indices (ConI) for ﬁvethe basis of two clinical CTs per patient (planning and one control
CT) were simulated and the beneﬁt of plan adaptionwas examined.
Setup errors were simulated applying isocenter shifts and
anatomical uncertainties were evaluated by recalculations on
control CTs. The authors concluded that the combination of
different errors can cause serious effects and recommended indi-
vidual surveillance of anatomy, dose recalculations and plan
adaptions. This recommendation is sustained by our study
analyzing several control CTs during the treatment course dis-
playing the consequences of anatomical changes as well as patient
positioning uncertainties on the dose distribution during frac-
tionated radiotherapy. Observed dose changes varied between in-
dividual patients which is also consistent to our ﬁndings.
Simone II et al. [3] compared adaptive to non-adaptive planning
with IMPT and IMXT for head and neck patients. One result was that
adaptive IMPToffers themost favorabledosequality.Our resultsagree
with that, assuming that the patient received the calculated dose.
In both above cited studies it was assumed that the anatomy
remained identical up to the day of the control CT and then untilpatients, corresponding mean values and standard deviations (right).
Figure 5. Trends of Dmax(1 cm3) to the spinal cord for ﬁve patients and corresponding mean values and standard deviations (right).
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anatomical changes there is a certain risk that the dose was not
delivered as planned until the fraction where adaptation started.
Our results obtained by recalculations on the 5th and 10th control
CT, indicate that adaption might already be relevant earlier during
the treatment course. Our investigations complement these studies
with patient data that reﬂects the actual clinical situation in posi-
tioning and anatomy in frequent intervals.
Contrary to the possible assumption that the anatomical
changes and its dosimetric consequences worsen throughout the
treatment, we showed that the decrease in quality is not neces-
sarily monotonic. Some assessed values “improved” again at the
following control CT, acquired ﬁve fractions later. Nevertheless the
general trend was obviously indicating to worsen towards the end
of the treatment, i.e. dosimetric quality indicators of treatment at
the last fraction were worse than in the beginning. The search for
explanations of the non-existingmonotony is challenging as well as
the search of correlations between dose criteria and weight loss
which could serve as a more distinctive indicator for replanning. As
patient weights ﬂuctuated considerably - due to side effects
(weight loss) and saline volume expansion during chemotherapy
(weight gain) - no signiﬁcant correlations were found in our study.Figure 6. Trends of mean dose to left and right parotid gland (PL and PR) oFor example, the plan recalculations for the patient with the most
stable weight (overall loss: 2 kg) did not lead to the most stable
dose distributions for both techniques, judged by the evaluated
dose criteria. Furthermore the underlying number of patients was
not sufﬁcient to derive correlations (e.g. with weight loss) with
statistical signiﬁcance.
Additionally, the anatomical changes cannot be viewed sepa-
rately from daily set-up variations that are likely to have a large
impact on the dose distributions as well. In our study, the main part
of set-up variations is corrected by IGRT (resulting in couch shifts)
and has therefore no impact on the dose distributions, i.e. their
absolute values (applied couch shifts) are not relevant for our
analysis. Nevertheless as not all variations can be corrected there
are remaining set up-errors inﬂuencing the delivered doses. In
comparison to the degree of impact caused by anatomical changes
and weight loss these are considered to have a rather small effect
though. Generally the impact of pure set-up uncertainties has been
studied elsewhere, e.g. in the study by Kraan et al. [15].
When to adapt a plan, i.e. to deﬁne the conditions where a plan
based on the current patient anatomy is no longer acceptable, will
remain a question to be investigated in the future. Especially for
IMPT the approach of this issue might be difﬁcult, where impacts off ﬁve patients e each symbol represents one parotid and one modality.
Figure 7. Dose distributions of the PTV area e initial plans (left) vs. recalculations
(right) at 20th fraction for protons (top) and photons (bottom). (Normalization:
100% ¼ 2 Gy; PTV contour: dark blue, patient contour: light blue).
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between fractions implicated.
The resulting IMPT coverage values of as low as 66.7% lead to
questions of clinical relevance and how this risk of underdosage
should be dealt with. One has to note that this was a single fraction,
and one has to take a closer look onto the calculated coverages over
all fractions. Here we can only estimate worst cases, and mean
coverages which were between 81% and 92% for IMPT. A more
accurate statement would demand recalculations on daily control
images and dose accumulation studies. Even though such extreme
deviations like the above stated 66.7% were exceptions throughout
the treatment period, they still show the need of accurate, high
quality IGRT and frequent control CTs, especially in proton therapy.
The dosimetric evaluation was performed for the PTV (as
motivated in the Methods section) of which rather the inner part
(i.e. the CTV) is of clinical relevance. Regarding the location of cold
spots, dose inhomogeneities of IMPT recalculations were spread all
over the target volume, i.e. within the CTV as well, while for IMXT
underdosagewas more pronounced in the peripheral regions of the
PTV, outside of the CTV. This indicates that PTV-based plan opti-
mization does not account sufﬁciently for all uncertainties in IMPT
which was also shown elsewhere [20].
Uncertainties in set-up and range are well-known issues for
IMPT and can be reduced by so-called robust optimization
[20,27e29]. Different robust optimization algorithms and methods
can improve the sensitivity of IMPT plans in terms of set-up errors
and range uncertainties by incorporating uncertainty information
into the planning process. Conducting the study with robust opti-
mizationmight lead to different dosimetric results. However, for our
study we do not expect large differences in the dosimetric conse-
quences and believe that the conclusionwould be similar. Themajor
impact on the dose distributions of our study is assumed to be
caused by anatomical changes which are only partly taken into ac-
count in some of the algorithms by estimating the caused range
uncertainties. For a detailed analysis, the study would have to be
repeated on initial plans calculated using a robust optimization tool.
Explanations for the great differences in the impact of
geometrical changes between IMPTand IMXT plans can be given by
the different physical properties of the particles and corresponding
features of plans. The great advantage of the protons, its ﬁnite range
and high spatial precision, is at the same time a well-known issue[14e20]. While changes of density and thickness of the traversed
matter lead to a slight deviation in dose values for photons, the
range of the protons is changed. Due to the applied intensity
modulation and spot scanning technique each IMPT ﬁeld consisted
of spots of different weights and energies. Density changes can
cause shifts of single spots and lead to unfavorable dose accumu-
lations from neighboring spots.
Our study was done on daily high quality IGRT by the tomo-
therapy unit, correcting the patient set-up with a very high quality.
Therefore our CT data represent almost the ideal case, with
frequent high quality imaging. To put this into perspective for
different clinical facilities of IMPT or IMXT it has to be emphasized
that the quality of IGRT depends strongly on the imaging possi-
bilities and their frequency, and that this might have a large impact
on the dose distributions, which may vary from our results.
Conclusion
We investigated the impact of interfractional geometrical
changes to dose distributions of IMPT and IMXT plans and
demonstrated differences in the consequences of the two irradia-
tion techniques. Although absolute alterations were larger in IMPT
plans, doses to OARs were more critical for IMXT plans. Tumor
coverage was less sensitive for IMXT plans; IMPT dose distributions
indicated a high risk for local underdosage. The amount of dosi-
metric changes differed largely between the individual patients, in
particular for IMPT plans.
For bothmodalities our data indicate the importance of frequent
control imaging and recalculations of treatment plans on control
CTs. Plan adaptions triggered by these recalculations might reduce
the underdosage of the tumor (most relevant for IMPT) and the
overdosage of OARs (in IMXT).
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